ENVOYA Trademark

Gene therapy products, namely, non-lipid polymer based nanoparticles for gene therapy; gene therapy products, namely polymer-based nanoparticles for medical, veterinary and pharmaceutical purposes; nucleic acid-containing products, namely RNA and DNA, for medical or veterinary purposes; gene therapy products for the treatment of cancer, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, or inflammatory diseases or disorders, namely, non viral vectors; nanoparticle products for medical or veterinary purposes, namely, non lipid polymer based nanoparticles; microparticle products for medical or veterinary purposes, namely, non lipid polymer based microparticles; nanoparticles for medical or veterinary purposes, namely, non lipid polymer based nanoparticles; microparticles for medical or veterinary purposes, namely, non lipid polymer based microparticles that facilitate the delivery of pharmaceutical preparations; nanoparticles that encapsulate a nucleic acid payload for delivery to a cell or tissue for medical or veterinary purposes; microparticles that encapsulate a nucleic acid payload for delivery to a cell or tissue for medical or veterinary purposes; nanoparticles that encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; microparticles that encapsulate nucleic acids, proteins, small molecules for medical or veterinary purposes; nanoparticles that encapsulate nucleic acids for medical or veterinary purposes; nanoparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes; microparticles that encapsulate cytotoxic payloads in cells for medical or veterinary purposes; diagnostic preparations and chemical and diagnostic reagents for clinical or medical laboratory use

Pharmaceutical research and development; research and development services in the field of pharmaceuticals; gene therapy research and development services; research and development services relating to the delivery of RNA and DNA therapeutics to patients; research and development services in the field of nanoparticles and microparticles; research and development services in the field of nucleic acid-containing particles; research and development services in the field of nucleic acids, proteins, and small molecules delivery; Development of nucleic acids, namely RNA and DNA, for encapsulating nanoparticles for targeted delivery; Research services in the field of nanoparticle characteristics; Research services in the field of microparticle characteristics; research and development services in the field of pharmaceutical preparations for the treatment of disease or disorders; research and development services in the field of pharmaceutical preparations for the treatment of cancer, muscular dystrophy, metabolic diseases or disorders, neurodegenerative diseases or disorders, cardiovascular diseases or disorders, infectious diseases, inflammatory diseases or disorders, rare diseases; scientific and technological services, namely, scientific research, analysis, optimization testing, development of protocols in the field of nucleic acids, proteins, and small molecules delivery to human cells; scientific and technological services, namely, scientific research, analysis, optimization testing, development of protocols in the field of protein delivery to human cells; Scientific and technological services, namely, research and design relating to scientific and technological services in the field of nucleic acids, proteins, and small molecules therapeutics